Syndex Bio closed a $15.5 million seed round led by Arch Venture Partners to commercialize mcPCR, a methylation‑preserving amplification method that copies 5‑methylcytosine onto the complementary strand during PCR. The startup says mcPCR improves recovery of methylated molecules and could boost sensitivity in epigenetic liquid biopsies and other diagnostics. The funding will expand R&D, build clinical workflows, and pursue applications in cell‑free DNA testing. Syndex positions mcPCR as a sample‑prep upgrade that could increase yield for methylation‑based cancer detection assays where preserving epigenetic marks is critical.